Loading
Health Catalyst, Inc. Stock: price and insider trades · United States
1 insider bought €91k of shares over the last 90 days, the latest filed 16 Sept 2026.
Health Catalyst, Inc.: what insiders have been doing
Health Catalyst, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 14 insiders have disclosed 40 filings since 18 October 2025.
Both sides are active: 1 purchase worth €91k and 2 sales worth €172k, from 1 insider and 2 insiders respectively. Netting one side against the other leaves €81k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 chief executive among the declarants. Larson-Green Julie filed the largest sale, €110k, on 9 December 2025.
The most recent open-market purchase was published on 16 September 2026, 31 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 40 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 7 purchases and 79 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 311.1 m USD and net income at -178.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
370
Thresholds
n/a
Buy Volume
€6M
7 ops. · all time
Sell Volume
€3M
79 ops. · all time
Who traded when
BuySaleLeSueur Daniel7 sales
Benjamin Landry6 sales
Linda Llewelyn4 sales
Gallagher Duncan2 sales
Jason Alger1 sale
Julie Larson-Green1 sale
+1 other insider
Since the insiders bought
- -46.2%Entry US$8.16 · Close at T+365 US$4.39
- -5.5%Entry US$12.52 · Close at T+365 US$11.83
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,962 of 24,148 companies
15.8
score / 100
Value7
Quality25
FCF yld-15%
Earn yld-131%
EV/EBITDA·
ROE-118%
Gross mgn49%
Net mgn-57%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.80
Analyst consensus
3 analysts2.60/5
US$1.50Target US$1.77(-2%)US$2.00
Income statement
RevenueUS$311.1M
Gross profitUS$151.7M49% margin
EBITDA-US$102.5M-33% margin
Net income-US$178M-90.6% margin
Valuation
PER (forward)240.0x
P/Book1.3x
Beta1.54
Balance sheet & cash
Market capUS$135.5M
Total debtUS$171.2M
Free Cash Flow-US$20.8M
Debt / Equity169%
Profitability & ownership
ROE-118.1%
ROA-3.0%
% insiders9.6%
% institutions71.3%
Last declaration on 5 October 2026
Declarations370 total
128,851 shares0Common StockSEC:0001582737-26-000002:0
2,747,385 shares0Common StockSEC:0001703807-26-000006:0
59,000 shares@ US$1.78710.079% mcap100.0% of flowCommon StockSEC:0001703807-26-000006:1
Canonical exit: 13 Dec 2026 (T+90)
35,244 shares@ US$1.67470.044% mcap29.7% of flowCommon StockSEC:0002086403-26-000008:0
35,244 shares@ US$1.67470.044% mcap49.8% of flowCommonSEC144:0001628280-26-061426
321 shares@ US$1.70360.0004% mcap0.3% of flowCommon StockSEC:0002086403-26-000007:0
17,973 shares@ US$1.70360.023% mcap3.1% of flowCommon StockSEC:0001839111-26-000004:0
9,766 shares0Common StockSEC:0001796545-26-000004:0
13,167 shares@ US$1.70360.017% mcap2.6% of flowCommon StockSEC:0001975281-26-000004:0
321 shares@ US$1.70360.0004% mcap0.5% of flowCommonSEC144:0001628280-26-059933
80,691 shares0Common StockSEC:0001320490-26-000003:0
80,691 shares0Common StockSEC:0002046471-26-000001:0
80,691 shares0Common StockSEC:0001397180-26-000001:0
80,691 shares0Common StockSEC:0001796545-26-000003:0
34,485 sharesCommon StockSEC:0002086403-26-000006:0
34,485 shares@ US$1.69180.046% mcap49.7% of flowCommonSEC144:0001628280-26-042293
336 shares@ US$1.37020.0005% mcap0.2% of flowCommon StockSEC:0002086403-26-000005:0
18,804 shares@ US$1.37020.025% mcap2.6% of flowCommon StockSEC:0001839111-26-000003:0
310 shares@ US$1.3450.0003% mcap0.2% of flowCommon StockSEC:0002086403-26-000004:1
1,124 shares0Common StockSEC:0002086403-26-000004:0
70,455 shares@ US$1.848165.5% of flowCommon StockSEC:0002086403-26-000003:0
13,836 shares@ US$1.65991.7% of flowCommon StockSEC:0001780878-26-000002:0
4,966 shares@ US$1.65994.1% of flowCommon StockSEC:0002086403-26-000002:0
20,838 shares@ US$1.65993.9% of flowCommon StockSEC:0001975281-26-000002:0
26,970 shares@ US$1.65994.5% of flowCommon StockSEC:0001839111-26-000002:0
25 of 370 declarations
About Health Catalyst, Inc.
Health Catalyst, Inc. (ticker: HCAT) is a U.S.-based healthcare data and analytics company listed on the **NASDAQ** in the **United States**. Founded in **2008** by healthcare analytics industry pioneers, the company is headquartered in **Salt Lake City, Utah**. Its core mission is to help healthcare organizations turn fragmented clinical, financial, and operational data into measurable improvement. Over time, Health Catalyst has evolved from a pure analytics vendor into a broader healthcare intelligence platform provider, combining software, cloud-based data infrastructure, and professional services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636422/000163642226000035/hcat-20251231.htm?utm_source=openai))
The company’s business lines center on a cloud-based data platform and a suite of applications and services designed for hospitals, health systems, and other care organizations. Health Catalyst enables clients to ingest, normalize, govern, and analyze healthcare data, then apply those insights to improve quality of care, lower costs, increase revenue, and manage population health. Its offerings include data platform capabilities, analytics and performance-improvement applications, patient engagement solutions, and implementation/consulting services. This mix gives the company recurring software exposure as well as services-led customer relationships. ([healthcatalyst.com](https://www.healthcatalyst.com/who-we-are?utm_source=openai))
Read moreShow less
From a competitive standpoint, Health Catalyst is positioned as a niche specialist rather than a horizontal enterprise software vendor. Its differentiation lies in deep healthcare domain expertise, a long operating history, and a track record of thousands of improvement projects tied to validated financial and clinical outcomes. Management describes the business as a healthcare intelligence company, and that framing reflects its attempt to compete on sector-specific workflows, outcomes, and security rather than on generic BI features alone. In practice, that places Health Catalyst alongside other healthcare data and workflow players, while its domain depth can be a meaningful barrier to entry. ([healthcatalyst.com](https://www.healthcatalyst.com/who-we-are?utm_source=openai))
Key products and strategic initiatives include the **Health Catalyst Ignite** platform, patient-engagement assets such as **Twistle**, and offerings associated with **Lumeon** and **Upfront**. In 2025, the company also launched ten AI-integrated data toolkits on the **Databricks Marketplace**, highlighting a clearer emphasis on AI-enabled, modular, and cloud-native use cases. Security and compliance remain important commercial differentiators in healthcare; Health Catalyst announced HITRUST r2 certifications for multiple offerings in late 2025, reinforcing its enterprise-grade positioning. ([healthcatalyst.com](https://www.healthcatalyst.com/news/unitypoint-health-to-unlock-next-phase-of-analytics-innovation-by-activating-health-catalyst-ignite-tm?utm_source=openai))
Geographically, the business is primarily U.S.-focused, serving American healthcare organizations and related networks. Recent company highlights show continued commercialization and product development in 2025, including the Catalyst Awards program and new client/partner activity. In March 2026, Health Catalyst reported fiscal 2025 revenue of **$311.1 million** and Adjusted EBITDA of **$41.4 million**. The company also underwent governance and leadership changes in 2026, including the appointment of **Ben Albert** as CEO and board-level changes in April 2026, which investors may view as part of an ongoing strategic reset and execution focus. ([ir.healthcatalyst.com](https://ir.healthcatalyst.com/news-releases/news-release-details/health-catalyst-announces-winners-2025-catalyst-awards?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
